AAlzheimer disease
First line
Alzheimer disease
First line
First-line for mild-to-moderate Alzheimer's disease per 2018, 2024, and SEN 2024 alongside donepezil and rivastigmine. Starting dose 8 mg once daily (extended-release) titrated to 24 mg over 4–8 weeks. Efficacy comparable to other AChE inhibitors. Some patients tolerate it better thanks to nicotinic modulation.
Sources
ICD-10: G30 · ICD-11: 8A20